For efficiency index, removal of the second period trial of krop et al, combination therapy had significant benefit for PFS in patients with PIK3CA mutation in tumor tissue (HR = 0.64, 95%CI: 0.4–0.98). This evidence concerns the gene PIK3CA and neoplasm.